Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
AbCellera Biologics Inc. - Common Shares
(NQ:
ABCL
)
4.340
-0.300 (-6.47%)
Streaming Delayed Price
Updated: 12:57 PM EST, Jan 23, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about AbCellera Biologics Inc. - Common Shares
< Previous
1
2
3
4
5
Next >
AbCellera to Report Full Year 2025 Financial Results on February 24, 2026
January 22, 2026
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause
January 12, 2026
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera and Bruker Reach Global Settlement of Patent Litigation
December 18, 2025
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026
December 08, 2025
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera Appoints Dr. Stephen Quake to its Board of Directors
November 10, 2025
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera Reports Q3 2025 Business Results
November 06, 2025
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera to Participate at Upcoming Investor Conferences in November and December 2025
October 07, 2025
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025
September 29, 2025
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer
September 10, 2025
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575
August 27, 2025
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera to Participate at Upcoming Investor Conferences in September
August 12, 2025
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms
August 07, 2025
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025
July 07, 2025
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575
May 30, 2025
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause
May 14, 2025
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera’s Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit
May 12, 2025
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting
May 09, 2025
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera Reports Q1 2025 Business Results
May 08, 2025
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025
April 29, 2025
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera to Participate at Upcoming Investor Conferences in May and June
April 08, 2025
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025
April 03, 2025
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025
March 25, 2025
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera Reports Full Year 2024 Business Results
February 27, 2025
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera to Participate at Upcoming Investor Conferences in March
February 11, 2025
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera to Report Full Year 2024 Financial Results on February 27, 2025
January 21, 2025
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology
January 13, 2025
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera to Present at Upcoming Investor Conferences in December and January
November 21, 2024
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024
November 07, 2024
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera Reports Q3 2024 Business Results
November 04, 2024
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera to Present at Upcoming Investor Conferences in November 2024
October 22, 2024
From
AbCellera Biologics Inc.
Via
Business Wire
< Previous
1
2
3
4
5
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
